BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting ...
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...
BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous ...
GlobalData on MSN
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...
Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.
D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...
NMPA accepts Akeso’s supplemental New Drug Application for gumokimab to treat active ankylosing spondylitis: Hong Kong Wednesday, January 21, 2026, 12:00 Hrs [IST] Akeso Inc, a ...
College applicants worry about sharing their race, gender and immigration status.
The Federal Energy Regulatory Commission will take comments through March 2 on a draft Supplemental Environmental Impact ...
Jacksonville Journal-Courier on MSN
Providers say feds’ new rural health care grants to Illinois won’t cover Medicaid cuts
Providers say $193 million Illinois will receive in federal grants will cover important updates for rural hospitals, but ...
La Plata County lost about $8 million in federal funding tied to the 2025-26 fiscal year, with some impacts expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results